Search alternatives:
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
0 decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
6 0 » 6 10 (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
0 decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
6 0 » 6 10 (Expand Search)
-
41
Expression of neurotrophins and their receptors was decreased in <i>Slitrk6</i>-deficient inner ear.
Published 2009“…The graphs depict mean + SD of 3 independent analyses. The mRNAs of <i>Bdnf</i> and <i>Ntf3</i> were significantly decreased in <i>Slitrk6</i>-deficient inner ear, whereas those of <i>Ntrk2</i> and <i>Ntrk3</i> were not. * <i>p</i><0.05, Student's <i>t</i>-test. …”
-
42
Zebrafish harboring homozygous mutations in <i>gdf6</i> exhibit decreased endurance.
Published 2014“…<i>gdf6<sup>−/−</sup></i> fish have approximately 50% lower endurance compared to <i>gdf6<sup>+/+</sup></i> siblings at each age (*p = 0.005, **p<0.01). …”
-
43
-
44
Image_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.tif
Published 2021“…</p>Results<p>ULT resulted in a mean (standard deviation) decrease in SU level (464.22 ± 110.21 μmol/L at baseline, 360.93 ± 91.66 μmol/L at the final visit, p <0.001) accompanied by a decrease in median (interquartile range) VFA [97.30 (81.15–118.55) at baseline, 90.90 (75.85–110.05) at the final visit, p < 0.001]. …”
-
45
-
46
-
47
-
48
-
49
-
50
-
51
-
52
Loss of C9orf72 decreases mTOR activation.
Published 2016“…C9orf72-/- MEF cells show a decrease in p-S6K1 when compared with wild-type cells. …”
-
53
-
54
-
55
-
56
-
57
-
58
Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.
Published 2016“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”
-
59
-
60